AstraZeneca/Daiichi's Enhertu shows survival benefit vs standard care in HER2+ gastric cancer patients, with 14.7 vs 11.4 ...

Immatics has shared new survival data from a Phase 1b trial of its melanoma cell therapy candidate, bolstering expectations for a registrational study that it recently started.

Gilead and Merck made a strong case for combining Trodelvy and Keytruda in the first-line setting for an aggressive form of ...

Appeals court denies HHS request to pause lower court order blocking federal agency restructuring plans that would cut 10,000 ...